Current concepts underlying the pathophysiology of acute Charcot neuroarthropathy in the diabetic foot and ankle

References

• Kaynak C, Birsel O, Guven MF, et al. An overview of the Charcot foot pathophysiology. Diabetic Foot Ankle. 2013;4:1–9.
   Google Scholar
• Larson SAM, Burns PR. The pathogenesis of Charcot neuroarthropathy: current concepts. Diabetic Foot Ankle. 2012;3:1–4.
   Google Scholar
• Sanders L, Frykberg R. The Charcot foot (pied Charcot). In: Bowker JH, Pfeifer MA, editors. Levin and O’Neal’s The Diabetic Foot. 7th ed. Philadelphia: Mosby Elsevier; 2007. p. 257–283.
   Google Scholar
• Jeffcoate WJ. Charcot neuro-osteoarthropathy. Diabetes Metab Res Rev. 2008;24(Suppl 1):S62–S65.
   PubMed Web of Science ®Google Scholar
• Nather A, Bee CS, Huak CY, et al. Epidemiology of diabetic foot problems and predictive factors for limb loss. J Diabetes Complic. 2008;22:77–82.
   PubMed Web of Science ®Google Scholar
• Wukich DK, Sung W. Charcot arthropathy of the foot and ankle: modern concepts and management review. J Diabetes Complic. 2008;23(6):409–426.
   PubMed Web of Science ®Google Scholar
• Petrova NL, Buxton-Thomas M, Moniz C, et al. Is there a systemic inflammatory response in the acute Charcot foot? Diabetes Care. 2007;30(4):997–998.
   PubMed Web of Science ®Google Scholar
• Hingsammer AM, Bauer D, Renner N, et al. Correlation of systemic inflammatory markers with radiographic stages of Charcot osteoarthropathy. Foot Ankle Int. 2016;37(9):924–928.
   PubMed Web of Science ®Google Scholar
• Jeffcoate WJ. Abnormalities of vasomotor regulation in the pathogenesis of the acute Charcot foot of diabetes mellitus. Lower Extremity Wounds. 2005;4(3):133–137.
   PubMedGoogle Scholar
• Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet. 2005;366:2058–2061.
   PubMed Web of Science ®Google Scholar
• Kon T, Cho TJ, Aizawa T, et al. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. Bone Mineral Res. 2001;16:1004–1014.
   PubMed Web of Science ®Google Scholar
• Gerstenfeld LC, Cho TJ, Kon T, et al. Impaired intramembranous bone formation during bone repair in the absence of tumor necrosis factor-alpha signaling. Cells Tissues Organs. 2001;169:285–294.
   PubMed Web of Science ®Google Scholar
• Mabilleau G, Petrova N, Edmonds ME, et al. *Number of circulating CD-14-positive cells and the serum levels of TNF-a are raised in the acute Charcot foot. Diabetes Care. 2011;34:33.
   Google Scholar
• Petrova NL, Petrov PK, Edmonds ME, et al. Inhibition of TNF-a reverses the pathological resorption pit profile of osteoclasts from patients with acute Charcot osteoarthropathy. Diabetes Res. 2015.
   PubMedGoogle Scholar
• Petrova NL, Dew TK, Musto RL, et al. Inflammatory and bone turnover markers in a cross-sectional and prospective study of acute Charcot osteoarthropathy. Diabetic Med. 2015;32:267–273.
   PubMed Web of Science ®Google Scholar
• Giganti MG, Liuni F, Celi M, et al. Changes in serum levels of TNF-alpha, IL-6, osteoprotegerin, RANKL and their correlation with radiographic and clinical assessment in fragility fractures and high energy fractures. Biol Regul Homeost Agents. 2012;26:671–680.
   PubMed Web of Science ®Google Scholar
• Folestad A, Alund M, Asterberg S, et al. **IL-17 cytokines in bone healing of diabetic Charcot arthropathy patients: a prospective 2-year follow-up study. J Foot Ankle Res. 2015;8(39):1–11.
   PubMed Web of Science ®Google Scholar
• Kuwabara T, Ishikawa F, Kondo M, et al. The role of IL-17 and related Cytokines in inflammatory autoimmune diseases. Mediators Inflamm. 2017.
   PubMed Web of Science ®Google Scholar
• Yang XO, Chang SH, Park H, et al. Regulation of inflammatory responses by IL-17F. Exp Med. 2008;205:1063–1075.
   PubMed Web of Science ®Google Scholar
• Jeffcoate WJ. Vascular calcification and osteolysis in diabetic neuropathy–is RANK-L the missing link? Diabetologia. 2004;47:1488–1492.
   PubMed Web of Science ®Google Scholar
• Connors JC, Hardy MA, Kishman LL, et al. Charcot pathogenesis: a study of in vivo gene expression. 2018. JFAS. 2018;57:1067–1072.
   Google Scholar
• Folestad A, Alund M, Asterberg S, et al. Role of Wnt/b-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients. Acta Orthop. 2015;86(4):415–425.
   PubMed Web of Science ®Google Scholar
• Gough A, Abraha H, Li F, et al. Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy. Diabetic Med. 1997;14(7):527–531.
   PubMed Web of Science ®Google Scholar
• Agholme F, Aspenberg P. Wnt signaling and orthopedics, an overview. Acta Orthop. 2011;82(2):125–130.
   PubMed Web of Science ®Google Scholar
• Agholme F, Li X, Isaksson H, et al. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res. 2010;25(11):2412–2418.
   PubMed Web of Science ®Google Scholar
• Agholme F, Isaksson H, Kuhstoss S, et al. The effects of Dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions. Bone. 2011;48(5):988–996.
   PubMed Web of Science ®Google Scholar
• Agholme F, Macias B, Hamang M, et al. Efficacy of a sclerostin antibody compared to a low dose of PTH on metaphyseal bone healing. Orthop Res. 2014;32(3):471–476.
   PubMed Web of Science ®Google Scholar
• Alikhani M, Alikhani Z, Boyd C, et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone. 2007;40:345–353.
   PubMed Web of Science ®Google Scholar
• Witzke KA, Vinik AI, Grant LM, et al. *Loss of RAGE defense: a cause of neuroarthropathy? Diabetes Care. 2011;34:1617–1621.
   PubMed Web of Science ®Google Scholar
• Archer AG, Roberts VC, Watkins PJ. Blood flow patterns in diabetic neuropathy. Diabetologia. 1984;27:564–567.
   Web of Science ®Google Scholar
• Shapiro SA, Stansberry KV, Hill MA, et al. Normal blood flow response and vasomotion in the diabetic Charcot foot. J Diabetes Complic. 1998;12:147–153.
   PubMed Web of Science ®Google Scholar
• Schinke T, Liese S, Priemel M, et al. Decreased bone formation and osteopenia in mice lacking a-calcitonin gene-related peptide. J Bone Mineral Res. 2004;19(12):2049–2056.
   PubMed Web of Science ®Google Scholar
• Irie K, Hara-Irie F, Ozawa H, et al. Calcitonin gene-related peptide (CGRP)-containing nerve fibers in bone tissue and their involvement in bone remodeling. Microsurg Res Tech. 2002;58:85–90.
   PubMed Web of Science ®Google Scholar
• LaFontaine J, Harkless LB, Sylvia VL, et al. Levels of endothelial nitric oxide synthase and calcitonin gene-related peptide in the Charcot foot: a pilot study. JFAS. 2008;46(5):424–429.
   Google Scholar
• Pereira M, Petretto E, Gordon S, et al. Common signalling pathways in macrophage and osteoclast multinucleation. J Cell Sci. 2015;131:1–11.
   Google Scholar
• Husheem M, Nyman JKE, Vaaraniemi J, et al. Characterization of circulating human osteoclast progenitors: development of an in vitro resorption assay. Calcified Tissue Int. 2005;76:222–230.
   PubMed Web of Science ®Google Scholar
• Uccioli L, Ruotolo V, Sinistro A, et al. Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot. Diabetes Care. 2010;33(2):350–355.
   PubMed Web of Science ®Google Scholar
• Pasquier J, Spurgeon M, Bradic M, et al. **Whole-methylome analysis of circulating monocytes in acute diabetic Charcot foot reveals differentially methylated genes involved in the formation of osteoclasts. Epigenomics. 2019;11(3):281–296.
   PubMed Web of Science ®Google Scholar
• Pasquier J, Thomas B, Hoarau-Vechot J, et al. *Circulating microparticles in acute diabetic Charcot foot exhibit a high content of inflammatory cytokines, and support monocyte-to-osteoclastic cell induction. Sci Rep. 2017;7:1–13.
   PubMed Web of Science ®Google Scholar
• Lee MS, Kim HS, Yeon JT, et al. GM-CSF regulates fusion of mononuclear osteoclasts into bone-resorbing osteoclasts by activating the Ras/ERK pathway. Immunol. 2009;183:3390–3399.
   Web of Science ®Google Scholar
• Takahashi N, Udagawa N, Akatsu T, et al. Role of colony-stimulating factors in osteoclast development. Bone Mineral Res. 1991;6:977–985.
   PubMed Web of Science ®Google Scholar
• Folestad A, Alund M, Asterberg S, et al. Offloading treatment is linked to activation of proinflammatory cytokines and start of bone repair and remodeling in Charcot arthropathy patients. Foot Ankle Res. 2015;8:72.
   PubMed Web of Science ®Google Scholar
• Wiwanitkit V. Effect of interleukin-2 and tumor necrosis factor-alpha on osteopontin: molecular function and biological process. Pediatr Int. 2008;50:213–215.
   PubMed Web of Science ®Google Scholar
• Pitocco D, Zelano G, Gioffre G, et al. **Association between osteoprotegerin G1181C and T245G polymorphisms and diabetic Charcot neuroarthropathy: a case-control study. Diabetes Care. 2009;32:1694–1697.
   PubMed Web of Science ®Google Scholar
• Korzon-Burakowska A, Jakobkiewicz-Banecka J, Fiedosiuk A, et al. *Osteoprotegerin gene polymorphism in diabetic Charcot neuroarthropathy. Diabetic Med. 2012;29:771–775.
   PubMed Web of Science ®Google Scholar
• Bruhn-Oslzewska B, Korzon-Burakowska A, Wegrzyn G, et al. Prevalence of polymorphisms in OPG, RANKL, and RANK as potential markers for Charcot arthropathy. Sci Rep. 2016;7(501):1–9.
   Google Scholar
• Mrozikiewicz-Rakowska B, Nehring P, Szymanski K, et al. 2018. Selected RANKl/RANK/OPG system genetic variants in diabetic foot patients. Diabetes Metab Disorder. 2018;17(2):287–296.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov identifier: NCT03174366.
   Google Scholar